PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session

Rhea-AI Summary

PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced the acceptance of their Phase 2b trial results for bentracimab for presentation at the American College of Cardiology Annual Scientific Session on April 2, 2022. The trial, involving 150 subjects, demonstrated the efficacy of bentracimab in reversing the antiplatelet effects of ticagrelor. The company plans to submit a Biologics License Application (BLA) to the FDA in mid-2022 as part of the ongoing development process for this potentially life-saving therapy.

Positive

• Phase 2b trial results show significant efficacy of bentracimab in reversing antiplatelet effects of ticagrelor.
• BLA submission to the FDA is targeted for mid-2022, indicating progression toward commercialization.

Negative

• None.

MALVERN, PA & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the Phase 2b trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old, has been accepted for presentation in a Late Breaking Clinical Research session at the American College of Cardiology Annual Scientific Session & Expo being held in Washington, D.C., April 2-4, 2022. The Phase 2b trial is a multi-center, randomized, double-blind, placebo-controlled study with 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of ticagrelor and low-dose aspirin. Top-line results from the Phase 2b trial were previously announced in November 2021.

Presentation Information

• Title: Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People
• Presenting Author: Deepak L. Bhatt, M.D., MPH, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School
• Session Title: Featured Clinical Research I
• Session Number: 403-10
• Date: April 2, 2022
• Session Time: 12:00 pm – 1:15 pm ET
• Presentation Time: 12:15 pm – 12:25 pm ET

“As part of the pivotal development program for bentracimab, which also includes the Phase 3 REVERSE-IT trial, the Phase 2b trial was designed to help answer important safety and efficacy questions related to bentracimab use in older subjects pre-treated with ticagrelor and aspirin therapy,” said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio. “We are pleased to have the opportunity to present the results from this trial to key stakeholders in the cardiology community at a high-profile medical congress like ACC.22.”

REVERSE-IT is a Phase 3, multi-center, open-label, prospective single-arm trial designed to study reversal of the antiplatelet effects of ticagrelor with bentracimab in patients who present with uncontrolled major or life-threatening bleeding or who require surgery or invasive procedure. Approximately 200 patients are being targeted to be enrolled from major health centers worldwide. In November 2021, PhaseBio presented interim results from the REVERSE-IT trial during a Late-Breaking Science Session at the 2021 American Heart Association Scientific Sessions. In December 2021, the REVERSE-IT interim results were subsequently published in NEJM Evidence, a new digital journal from the NEJM (New England Journal of Medicine) Group. The Company is commencing preparation of the BLA and targeting a BLA submission to the U.S. Food and Drug Administration (FDA) in mid-2022.

Bentracimab has been studied in Phase 1 and Phase 2 clinical trials and has demonstrated the potential to bring life-saving therapeutic benefit through immediate and sustained reversal of the antiplatelet activity of ticagrelor, potentially mitigating concerns regarding bleeding risks associated with the use of this antiplatelet drug. Additionally, in a translational study, bentracimab achieved equivalent reversal of branded ticagrelor and multiple ticagrelor generics.

About Bentracimab (PB2452)

Bentracimab is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. In a Phase 1 clinical trial, bentracimab demonstrated the potential to bring life-saving therapeutic benefit through immediate and sustained reversal of ticagrelor’s antiplatelet activity, mitigating concerns regarding bleeding risks associated with the use of this antiplatelet drug. Data from the Phase 1 clinical trial of bentracimab in healthy volunteers was published in the New England Journal of Medicine in March 2019. In April 2019, bentracimab received Breakthrough Therapy Designation from the FDA. In September 2019, PhaseBio completed a Phase 2a trial in which bentracimab was investigated in healthy, older subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin. Additionally, the Phase 2a trial investigated a bentracimab regimen for the reversal of supratherapeutic doses of ticagrelor in healthy younger subjects. In November 2021, PhaseBio completed a Phase 2b trial in which bentracimab was investigated in healthy, older subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin. In all active treatment arms in both the Phase 2a and Phase 2b trials, bentracimab achieved immediate and sustained reversal of the antiplatelet effects of ticagrelor and was generally well-tolerated, with only minor adverse events reported. These results are consistent with the results observed in healthy younger subjects treated with ticagrelor in the previously published Phase 1 trial. PhaseBio initiated REVERSE-IT, a pivotal Phase 3 clinical trial of bentracimab, in March 2020 to support a potential Biologics License Application for bentracimab in both major bleeding and urgent surgery indications. Interim results from the Phase 3 REVERSE-IT trial were presented in November 2021 and subsequently published in NEJM Evidence in December 2021.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. PhaseBio’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “potential,” “projects,” “target,” “will,” “would” and “future” or similar expressions are intended to identify forward-looking statements.

Forward-looking statements include statements concerning or implying the conduct or timing of our clinical trials and our research, development and regulatory plans for our product candidates, the timing of availability or disclosure of data from those clinical trials and the timing of planned regulatory submissions, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed, marketed and commercialized. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.

Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021. These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005430/en/

Investor Contact:

John Sharp

PhaseBio Pharmaceuticals, Inc.

Chief Financial Officer

(610) 981-6506

john.sharp@phasebio.com

Media Contact:

Will Zasadny

Canale Communications, Inc.

(619) 961-8848

will.zasadny@canalecomm.com

Source: PhaseBio Pharmaceuticals, Inc.

FAQ

What are the results of the Phase 2b trial for bentracimab by PhaseBio Pharmaceuticals?

The Phase 2b trial revealed that bentracimab effectively reverses the antiplatelet effects of ticagrelor in older adults.

When will the Phase 2b trial results for bentracimab be presented?

The results will be presented on April 2, 2022, at the American College of Cardiology Annual Scientific Session.

What is the next step for PhaseBio Pharmaceuticals regarding bentracimab?

PhaseBio plans to submit a Biologics License Application (BLA) to the FDA in mid-2022.

What is bentracimab and its significance in cardiopulmonary treatments?

Bentracimab is a monoclonal antibody aimed at reversing ticagrelor's antiplatelet effects, offering potential life-saving benefits during emergencies.